Please complete the Quiz.
Question 1- About the discontinuation rates in the ENESTnd study:
Question 2- True or False. In the ENESTnd trial, progression in the imatinib arm was approximately 5 times higher than in the nilotinib arm
Thank you for completing the quiz.
Evolution of CML treatment and goals of therapy in 2014:
View Session
Back
Dr. Gianantonio Rosti
Department of Hematology and Oncology
'L. and A. Serà gnoli' St Orsola University Hospital - Bologna